GEA
VIR icon

Glen Eagle Advisors’s Vir Biotechnology VIR Stock Holding History

Glen Eagle Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-65
Closed -$3.33K – 1064
2021
Q1 		$3.33K Sell
65
-65
-50% -$3.5K ﹤0.01% 821
2020
Q4 		$3.48K Buy
+130
New +$4.22K ﹤0.01% 785

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Glen Eagle Advisors's VIR Position: Q2 2021 in Review

Glen Eagle Advisors sold out of Vir Biotechnology (VIR) in Q2 2021, closing a stake of 65 shares — an estimated $3.33K sold.

Glen Eagle Advisors first reported a position in VIR in Q4 2020 and held it in 2 quarters. The position peaked at $3.48K in Q4 2020. 166 funds tracked by Wall St. Rank hold VIR as of Q2 2021.

  • Glen Eagle Advisors reported no remaining Vir Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 65 Vir Biotechnology shares in Q2 2021, an estimated $3.33K.
  • Glen Eagle Advisors first reported a position in Vir Biotechnology in Q4 2020 and held it in 2 quarters.
  • Glen Eagle Advisors's Vir Biotechnology position peaked at $3.48K in Q4 2020.
  • 166 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2021.

Based on Glen Eagle Advisors's 13F filing for Q2 2021, filed 13 Aug 2024.